CL2007002862A1 - Uso del factor de crecimiento epidermico (egf) para tratar neuropatia sensitivo-motora, dolorosa y manifestaciones de neuritis isquemicas; composicion farmaceutica que comprende egf; y uso de la composicion antes dicha. - Google Patents

Uso del factor de crecimiento epidermico (egf) para tratar neuropatia sensitivo-motora, dolorosa y manifestaciones de neuritis isquemicas; composicion farmaceutica que comprende egf; y uso de la composicion antes dicha.

Info

Publication number
CL2007002862A1
CL2007002862A1 CL200702862A CL2007002862A CL2007002862A1 CL 2007002862 A1 CL2007002862 A1 CL 2007002862A1 CL 200702862 A CL200702862 A CL 200702862A CL 2007002862 A CL2007002862 A CL 2007002862A CL 2007002862 A1 CL2007002862 A1 CL 2007002862A1
Authority
CL
Chile
Prior art keywords
egf
ischemical
neuritis
manifestations
motor
Prior art date
Application number
CL200702862A
Other languages
English (en)
Inventor
Montequin Jose Ignac Fernandez
Original Assignee
Ct Ingenieria Genetica Biotech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38925545&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2007002862(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ct Ingenieria Genetica Biotech filed Critical Ct Ingenieria Genetica Biotech
Publication of CL2007002862A1 publication Critical patent/CL2007002862A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1808—Epidermal growth factor [EGF] urogastrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/485—Epidermal growth factor [EGF] (urogastrone)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/12—Growth hormone, growth factor other than t-cell or b-cell growth factor, and growth hormone releasing factor; related peptides
CL200702862A 2006-10-03 2007-10-03 Uso del factor de crecimiento epidermico (egf) para tratar neuropatia sensitivo-motora, dolorosa y manifestaciones de neuritis isquemicas; composicion farmaceutica que comprende egf; y uso de la composicion antes dicha. CL2007002862A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU20060192A CU23526B6 (es) 2006-10-03 2006-10-03 Método para la restauración morfofuncional de nervios periféricos en la neuropatía diabética

Publications (1)

Publication Number Publication Date
CL2007002862A1 true CL2007002862A1 (es) 2008-05-23

Family

ID=38925545

Family Applications (1)

Application Number Title Priority Date Filing Date
CL200702862A CL2007002862A1 (es) 2006-10-03 2007-10-03 Uso del factor de crecimiento epidermico (egf) para tratar neuropatia sensitivo-motora, dolorosa y manifestaciones de neuritis isquemicas; composicion farmaceutica que comprende egf; y uso de la composicion antes dicha.

Country Status (20)

Country Link
US (2) US8642552B2 (es)
EP (1) EP2075004B1 (es)
JP (1) JP5508853B2 (es)
KR (1) KR101464208B1 (es)
CN (1) CN101573130B (es)
AR (1) AR063088A1 (es)
AT (1) ATE544462T1 (es)
AU (1) AU2007304640B2 (es)
BR (1) BRPI0719816B8 (es)
CA (1) CA2665117C (es)
CL (1) CL2007002862A1 (es)
CU (1) CU23526B6 (es)
DK (1) DK2075004T3 (es)
ES (1) ES2386058T3 (es)
MX (1) MX2009003678A (es)
PL (1) PL2075004T3 (es)
PT (1) PT2075004E (es)
RU (1) RU2460536C2 (es)
WO (1) WO2008040260A1 (es)
ZA (1) ZA200902311B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101252740B1 (ko) * 2011-05-25 2013-04-11 연세대학교 산학협력단 센서 및 센싱방법
EP2737895A1 (en) * 2012-11-30 2014-06-04 Praxis Pharmaceutical, S.A. Microparticles with EGF, method of preparation and use
JP2016507493A (ja) * 2012-12-21 2016-03-10 スィーケフス ソールラン ホーエフ 神経障害及び疼痛のｅｇｆｒ標的治療
US9387151B2 (en) 2013-08-20 2016-07-12 Anutra Medical, Inc. Syringe fill system and method
EP3808338A1 (en) 2013-09-11 2021-04-21 Eagle Biologics, Inc. Liquid protein formulations containing ionic liquids
USD763433S1 (en) 2014-06-06 2016-08-09 Anutra Medical, Inc. Delivery system cassette
USD774182S1 (en) 2014-06-06 2016-12-13 Anutra Medical, Inc. Anesthetic delivery device
USD750768S1 (en) 2014-06-06 2016-03-01 Anutra Medical, Inc. Fluid administration syringe
WO2016054259A1 (en) 2014-10-01 2016-04-07 Arsia Therapeutics, Inc. Polysaccharide and nucleic acid formulations containing viscosity-lowering agents
RU2585421C1 (ru) * 2014-12-24 2016-05-27 Артур Владимирович Маргасов Способ восстановления поврежденного нерва

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5130298A (en) * 1989-05-16 1992-07-14 Ethicon, Inc. Stabilized compositions containing epidermal growth factor
SE9601243D0 (sv) 1996-03-29 1996-03-29 Hans Arne Hansson Promotion of regeneration of organized tissues
WO1999036513A1 (en) * 1998-01-20 1999-07-22 Aurx, Inc. A herpes virus vector
US6444205B2 (en) * 1998-09-30 2002-09-03 Diacrin, Inc. Transplantation of neural cells for the treatment of chronic pain or spasticity
SE9804064D0 (sv) 1998-11-25 1998-11-25 A & Science Invest Ab Medicinal product and method for treatment of conditions affecting neural stem cells or progenitor cells
AU782819B2 (en) * 1999-04-15 2005-09-01 Caritas St. Elizabeth's Medical Center Of Boston, Inc. Angiogenic growth factors for treatment of peripheral neuropathy
WO2002012335A2 (en) * 2000-08-10 2002-02-14 Pharmacia Corporation A NEW EGF MOTIF REPEAT PROTEIN OBTAINED FROM A cDNA LIBRARY FROM HS-5 STROMAL CELL LINE
CU23157A1 (es) 2001-01-03 2006-07-18 Ct Ingenieria Genetica Biotech COMPOSICION FARMACéUTICA PARA EL TRATAMIENTO DEL DANO TISULAR DEBIDO A FALTA DE IRRIGACION SANGUINEA ARTERIAL
JP2006152001A (ja) * 2001-03-12 2006-06-15 Institute Of Gene & Brain Science 神経損傷の治療薬
EP1374898B1 (en) * 2001-03-12 2007-06-27 Institute of Gene and Brain Science Use of interleukin-12 for treating nerve damage
HK1077740A1 (en) * 2001-12-20 2006-02-24 Ct Ingenieria Genetica Biotech Use of epidermal growth factor in the manufacture of a pharmaceutical injection composition for preventing diabetic limb amputation
US7465463B2 (en) 2002-09-04 2008-12-16 Polyheal, Ltd. Compositions comprising microspheres with anti-inflammatory properties for healing of ocular tissues
US20070122487A1 (en) * 2003-03-19 2007-05-31 University Of Kentucky Research Foundation (Poly(acryloyl-hydroxyethyl starch)-plga composition microspheres
EP2289526B1 (en) * 2003-04-25 2014-06-11 The University of Pittsburgh Muscle derived cells (mdcs) for promoting and enhancing nerve repair and regeneration.
EP1781322A4 (en) * 2004-08-06 2009-09-30 Novozymes Biopharma Au Ltd METHOD OF TREATING DIABETES
CN101150954A (zh) * 2005-01-21 2008-03-26 西北大学 包封细胞的方法和组合物
KR100765496B1 (ko) * 2005-12-09 2007-10-10 경희대학교 산학협력단 히레귤린 베타1의 ｅｇｆ-성 도메인 펩타이드를 암호화하는ｄｎａ 서열을 포함하는 재조합 아데노바이러스 및 이를포함하는 신경세포 분화 및 재생용 약학 조성물

Also Published As

Publication number Publication date
CN101573130B (zh) 2012-10-31
US9034826B2 (en) 2015-05-19
EP2075004A1 (en) 2009-07-01
CU23526B6 (es) 2010-05-19
RU2460536C2 (ru) 2012-09-10
ATE544462T1 (de) 2012-02-15
JP2010505773A (ja) 2010-02-25
US20100136062A1 (en) 2010-06-03
CA2665117A1 (en) 2008-04-10
PL2075004T3 (pl) 2012-09-28
ZA200902311B (en) 2010-04-28
JP5508853B2 (ja) 2014-06-04
DK2075004T3 (da) 2012-05-14
ES2386058T3 (es) 2012-08-08
CA2665117C (en) 2015-04-14
PT2075004E (pt) 2012-05-02
KR20090103862A (ko) 2009-10-01
MX2009003678A (es) 2009-04-22
BRPI0719816B8 (pt) 2021-05-25
KR101464208B1 (ko) 2014-12-04
AU2007304640A1 (en) 2008-04-10
US8642552B2 (en) 2014-02-04
BRPI0719816A2 (pt) 2015-09-08
CN101573130A (zh) 2009-11-04
AR063088A1 (es) 2008-12-23
BRPI0719816B1 (pt) 2018-04-24
AU2007304640B2 (en) 2013-01-17
EP2075004B1 (en) 2012-02-08
US20140105990A1 (en) 2014-04-17
WO2008040260A1 (es) 2008-04-10
RU2009116646A (ru) 2010-11-10

Similar Documents

Publication Publication Date Title
CL2007002862A1 (es) Uso del factor de crecimiento epidermico (egf) para tratar neuropatia sensitivo-motora, dolorosa y manifestaciones de neuritis isquemicas; composicion farmaceutica que comprende egf; y uso de la composicion antes dicha.
DOP2010000304A (es) Composiciones y metodos de preparacion y uso de las mismas
CL2007002635A1 (es) Compuestos derivados de quinazolinona e isoquinolinona, moduladores de la actividad del eje hpa; composicion farmaceutica que los comprende; y su uso en el tratamiento y/o prevencion relacionado con estres o depresion.
CL2013003372A1 (es) Compuestos derivados de espiro-[1,3]-oxacinas y espiro-[1,4]-oxacepinas, inhibidores de bace1 y/o bace2; composicion farmaceutica; procedimiento para prepararlos; y su uso en el tratamiento y/o la profilaxis de la enfermedad de alzheimer y diabetes.
GT201400111A (es) Triazolopiridinas sustituidas
CO6280490A2 (es) 4-(4-ciano-2-tioaril)dihidropirimidinonas y su uso
CL2007002188A1 (es) Compuestos derivados de heteroarilaminas; procedimiento de preparacion; composicion farmceutica; y uso del compuesto para tratar el crecimiento celular anormal.
CL2007002971A1 (es) Compuestos derivados de aminometil-4-imidazol; procedimiento de preparacion; composicion farmaceutica que los contiene; y su uso para tratar depresion, ansiedad, trastorno bipolar, entre otras.
CL2009000349A1 (es) Compuestos derivados de 4,5-dihidro-oxazol-2-ilamina; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer.
UY33597A (es) Compuestos y composiciones como inhibidores de la trk
CL2012002189A1 (es) Compuestos derivados de pirrolidina-2-carboxamidas sustituidas; inhibidores de la interaccion mdm2-p53; composicion farmaceutica; y su uso para el tratamiento del cancer, en particular de tumores solidos.
CL2011002787A1 (es) Compuestos derivados de 1-cianoetilheterociclilcarboxamida sustituidos, inhibidores de dipeptidilpeptidasa i (dppi) o catepsina c; composicion farmaceutica; combinacion faramceutica; y su uso en el tratamiento del asma, la enfermedad obstructiva cronica o la rinitis alergica.
CR11802A (es) Derivados de indazoles sustituidos con fenilo o piridinilo
DOP2011000176A (es) Compuestos organicos
CL2013001295A1 (es) Compuestos derivados de 2,3-dihidromidazo (1,2-c) quinazolina sustituidos con aminoalcoholes; compuesto intermediario y su uso; composicion farmaceutica; combinacion farmaceutica; y su uso para tratar trastornos hiperproliferativos y enfermedades asociadas a la angiogenesis.
DOP2016000253A (es) Nuevos compuestos
EA033311B1 (ru) Производные бензоксаборола в качестве антибактериальных средств
CL2008002430A1 (es) Compuestos derivados de bencenosulfonamida, inhibidores de catepsina c; composicion farmaceutica que los comprende; y su uso para el tratamiento de la epoc.
CO6300844A2 (es) Dihidropirazolonas sustituidas como inhibidores de hif-propil-4-hidroxilasa
ECSP099616A (es) Estabilización de vitamina b12
CL2007002970A1 (es) Compuestos derivados de aminometil-4-imidazol; procedimiento de preparacion; composicion farmaceutica que los contiene; y su uso para tratar depresion, ansiedad, trastorno bipolar, entre otras.
BR112018002983A2 (pt) composição compreendendo uma lactama e um álcool
CL2008002726A1 (es) Compuestos derivados de isoquinolinilo e isoindolinilo, antagonistas de histamina-3; procedimiento de preparacion de dichos compuestos; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar trastornos del sistema nervioso c
CL2011002911A1 (es) Compuestos derivados de benzamidas, inhibidores de serina proteasa; composición farmacéutica; uso del compuesto para tratar cáncer.
CL2011002617A1 (es) Compuestos derivados de arilsulfonamidas 2,5-disustituidas, moduladores del receptor ccr3; composicion farmaceutica que los comprende; y uso del compuesto o de la composicion para prevenir y/o tratar un trastorno inflamatorio o inmunoregulador tal como asma, rinitis, vih, enfermedad de alzheimer, entre otros.